Clinical Report: Reducing Injections in Wet AMD

Overview

The DAVIO2 trial demonstrated that EYP-1901 significantly reduces the treatment burden for patients with wet age-related macular degeneration (AMD), allowing for only 1 to 2 supplemental injections per year after initial dosing. This represents a substantial improvement over the average of 10 injections required prior to the trial.

Background

Wet age-related macular degeneration (AMD) is a leading cause of irreversible vision loss in older adults, necessitating frequent intravitreal injections of anti-VEGF therapies. The high treatment burden often leads to patient non-compliance and worsened visual outcomes. Innovations such as tyrosine kinase inhibitors like EYP-1901 aim to reduce this burden while maintaining effective disease control.

Data Highlights

Key Findings

• EYP-1901 is a potent anti-VEGF/pan-VEGF inhibitor designed for sustained release over approximately 6 months.
• Patients in the DAVIO2 trial experienced a significant reduction in the number of injections needed after treatment.
• The trial participants had a high treatment burden prior to enrollment, averaging 10 injections per year.
• Post-treatment, patients required only 1 to 2 supplemental injections annually, indicating improved treatment adherence potential.
• Future phase 3 trials are anticipated to further validate these findings and assess long-term outcomes.

Clinical Implications

The findings from the DAVIO2 trial suggest that EYP-1901 could transform the management of wet AMD by significantly reducing the frequency of required injections. This may enhance patient adherence to treatment regimens and improve overall visual outcomes.

Conclusion

EYP-1901 represents a promising advancement in the treatment of wet AMD, potentially alleviating the burden of frequent injections and improving patient quality of life. Ongoing research will be critical to confirm these benefits in larger populations.

References

1. Avni Finn, MD, Diana Do, MD, Retinal Physician, 2025 -- Video: Reducing Injections in Wet AMD
2. David A. Eichenbaum, MD, Retinal Physician, 2021 -- Assessing AMD Therapies
3. Priya Vakharia, MD, Retinal Physician, 2021 -- Anti-VEGF Therapy & AMD
4. Lucas W. Rowe, MD, Thomas A. Ciulla, MD, MBA, Retinal Physician, 2024 -- Improving Durability of Drugs in Wet AMD
5. Oregon Health & Science University, 2025 -- Age-Related Macular Degeneration Preferred Practice Pattern®
6. Ophthalmology Management — QUICK HITS
7. EYLEA HD® (aflibercept) Injection 8 mg Applications for Expanded U.S. Label
8. A review of the DAVIO 2 phase 2 trial results
9. Age-Related Macular Degeneration Preferred Practice Pattern® - Oregon Health & Science University